NextCure

NXTC · NASDAQ

$5.44−$0.23 (−4.06%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $5.67

NXTC analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 3 analysts

Average $20.40 (+275.0% upside)

Low: $20.20
Now: $5.44
High: $21.00

Upgrades and downgrades

The latest rating actions, newest first

NXTC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
LUCID CAPITAL MARKETS	May 11, 2026	Initiates	Buy	$25.00	50%
Ladenburg Thalmann	Nov 7, 2025	Upgrade	Neutral → Buy	$18.00	38%

The case for and against

Updated Jan 5, 2026

Bull case

NextCure Inc's recent acquisition of global rights to SIM0505 outside Greater China positions the company to potentially receive up to $745 million in upfront and milestone payments, along with tiered royalties that can reach double-digit percentages on net sales. The firm is also enhancing value for its antibody-drug conjugates (ADCs) and demonstrating promising preclinical data with robust anti-tumor activity and a favorable safety profile across multiple solid tumor models. Furthermore, NextCure is advancing its development pipeline with plans to initiate Phase I studies for SIM0505 in the U.S. after its ongoing dose-escalation studies in China.

Bear case

NextCure Inc has seen a significant reduction in its projected enterprise value, revised down to $37.5 million from a previous estimate of $75 million, which raises concerns regarding its financial stability and future growth potential. The company is also facing inherent risks associated with the clinical development of its therapies, which may fail to achieve anticipated results. Additionally, the substantial decrease in the price target, adjusted from $36 to $15, further reflects a negative outlook on the company's ability to deliver on its projected performance.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.